Simvastatin hydroxy acid (SVA), the pharmacologically active form of simvastatin (SV), is a potent inhibitor of 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A reductase and is formed on hydrolysis of the orally administered SV. In this article, we report the structural characterization of two new dihydroxy glutathione adducts and a trihydroxy derivative of SVA, all found in rat bile. Metabolite I is 5␤,6␤-dihydroxy-4a␣-glutathione-SVA, and metabolite II is a pentanoic acid derivative of metabolite I. The two identified GSH conjugates accounted for 16 and 9% in males and 11 and 5% in females of the total radioactivity (metabolites I and II, respectively). Metabolite III is 3,5␤,6␤-dihydrotriol-SVA and accounts for 2% (male) and 4% (female) of the total dose in rats. Of these three newly identified metabolites, only metabolite III was also observed in dog bile.
spectral analyses were performed using electrospray ionization in the negative ion mode. The electrospray ionization ionizing voltage was 2.5 kV, and the heated capillary temperature was 160°C. The isolation width and collision energy values were set at 3 and 25%, respectively, for the MS/MS experiments. Detection and identification of the metabolites were based on radioactive peak monitoring, molecular ion detection, and visual recognition of the 14 C/ 12 C isotopic "goal-posts" in the mass spectrum resulting from the 1:1 ratio of 14 C/ 12 C in the SVA dosing solution. Metabolite Isolation for NMR. Metabolite isolation for NMR was accomplished with two rounds of HPLC purification. The initial purification was done under the HPLC conditions described above. Fractions containing the metabolites were collected, pooled, dried under a stream of nitrogen gas, individually reconstituted in 200 l of 0.1% formic acid, and repurified. The LC conditions for the repurification included a 2.0 ϫ 250-mm Betasil column and a linear gradient from 23 to 50% B. Fractions were collected based on a UV peak at 240 nm. The collected fractions were again dried under a stream of N 2 gas and used immediately for NMR analysis. Metabolite III was isolated from male dog bile using the same isolation procedures.
NMR Analysis. NMR spectra were obtained using an Inova (11.7 T/500 MHz) 51-mm narrow-bore spectrometer (Varian Instruments, Palo Alto, CA) equipped with a 3-mm inverse detection probe (MIDG-3; Nalorac Corporation, Martinez, CA). The metabolites were dissolved in 160 l of chilled CD 3 OD, and data was acquired at 3°C to minimize sample degradation.
1 H 1D, 2D total correlation spectroscopy (TOCSY), [
13 C] 1 H heteronuclear multiple quantum coherence (HMQC), and 2D transverse rotating Overhauser effect spectroscopy (ROESY) data sets (Summers et al., 1986; Hwang and Shaka, 1992) were collected for metabolites I and II. For metabolite III, 1 H 1D TOCSY and a 1D nuclear Overhauser effect (NOE) difference spectra were collected.
Results
Identification of SVA Metabolites. Metabolite I. The molecular ion region of a full scan MS spectrum ( Fig. 2A ) of metabolite I shows the presence of a molecular ion [M Ϫ H] Ϫ ϭ 774 Da and a corresponding 14 C peak at 776 Da in an approximately 1:1 ratio. MS/MS fragmentation of the peak at 774 Da shows peaks indicative of a glutathione moiety attached to the metabolite (Fig. 2B) , including the following: ions at m/z 306 (
, and a neutral loss of 129 (m/z 645). The apparent molecular weight of this metabolite corresponds to an addition of two oxygen atoms and a molecule of GSH to the parent SVA.
Identifiable 1 H and 13 C chemical shifts for metabolite I are listed in Table 1 . Protons 4 and 6 in the dihydroxy heptanoic acid side chain have signature chemical shifts in the SV lactone (H4, 4.25 ppm; H6, 4.62 ppm) and SVA (H4, 4.08 ppm; H6, 3.69 ppm). Protons 4 and 6 of metabolite I have chemical shifts (␦) of 4.25 and 4.64 ppm, and hence, the metabolite as characterized by NMR is in the lactone form. The connectivity involving the heptanoic lactone side chain protons can be fully traced in the metabolite TOCSY spectrum (Fig. 4A) .
Relative to SVA, the proton chemical shifts of the dimethyl butyric acid side chain of metabolite I were unaltered. The peaks correspond- ing to the 3Ј-and 4Ј-protons appeared as a nonfirst-order multiplet in the metabolite 1D 1 H spectrum (Fig. 3 ) and were well resolved in the [ 13 C] 1 H HMQC spectrum (not shown). The 4Ј, 3Ј, 2Ј, 2ЈMe, 1Ј, 8Јa, 8Ј, and 7Ј connectivity can be traced in the 2D TOCSY spectrum (Fig.  4A) , and hence, the site of oxidation and glutathione addition can be narrowed to positions 4Јa, 5Ј, and 6Ј.
The 6Ј-proton peak at 2.42 ppm in SVA is absent in the metabolite spectra. The peak corresponding to the 6ЈMe is a doublet at 1.08 ppm in SVA but moves downfield to 1.62 ppm and appears as a singlet in the metabolite, suggesting an OH addition at the 6Ј-position and an OH or SG in the neighboring position. The SVA peak at 5.49 ppm (5ЈH) has disappeared and a new singlet is seen at 3.72 ppm in the metabolite 1 H spectrum (Fig. 3 ). This new singlet had a correlated 13 C peak at 77.4 ppm in the HMQC spectrum (not shown). The 1 H and 13 C chemical shifts rule out a GS addition at the 5Ј-position and instead indicate an OH addition. In the ROESY spectrum, cross peaks are seen from the 5ЈH (3.72 ppm) to the 6ЈMe (1.62 ppm) and the glutathione cЈ methylene (2.82 ppm, 3.22 ppm). In addition, ROE 4B ) are also seen from the 4ЈH (5.73 ppm) to the glutathione cЈ proton (3.22 ppm) and the 5ЈH (3.72 ppm). These observations together indicate that the glutathione addition occurs at the 4Јa-position and reaffirms OH additions to the 5Ј-and 6Ј-positions. This assignment is also supported by the up-field shift of the 8Јa-peak from 2.33 ppm to 1.88 ppm, which would occur due to loss of the ⌬ 4Јa,5Ј double bond. In addition, the ROESY data indicate that 6ЈMe, 5ЈH, and the 4Јa-SG are in the ␣-configuration (syn with respect to each other).
Metabolite I has been shown to be in its hydroxy acid form in rat bile. Under the LC-MS conditions, the hydroxy acid and lactonized forms of metabolite I have retention times of 9.7 and 16.0 min, respectively. The conversion from the hydroxy acid to the lactone form is favored under acidic conditions and thus has occurred during the purification, which was carried out under acidic conditions. An aliquot of the NMR sample was subjected to base hydrolysis and resulted in the hydroxy acid form, as confirmed by its retention time and MS spectrum. Thus, metabolite I has been identified as 5Ј␤,6Ј␤-dihydroxy-4Јa␣-glutathione-SVA and is shown in Fig. 1 Table 1 . In metabolite II, the geminal methyl groups in the butyric acid ester moiety are identifiable and intact. The chemical shifts of all the glutathione protons are identifiable in the metabolite spectra. Also, the 4Ј-3Ј-2Ј-2ЈMe-1Ј-8Јa-8Ј-7Ј connectivity can be traced in the 2D TOCSY spectrum, and hence, the decalin ring is intact.
NMR features of the decalin ring for metabolite II are similar to those of metabolite I. The key features are as follows: 1) the parent SVA peak at 5.49 ppm (5ЈH) has disappeared, and a new singlet is seen at 3.71 ppm in the 1 H spectrum, which has a 13 C correlated peak at 77.5 ppm; 2) ROESY cross peaks are seen from the singlet at 3.71 ppm (assigned to 5ЈH) to the 6ЈMe (1.61 ppm) and to the cЈ methylene (2.82, 3.21 ppm); and 3) ROESY cross peaks are also seen from the 4ЈH (5.72 ppm) to the cЈ protons in glutathione and the 5ЈH (3.71 ppm). These changes suggest that the glutathione addition occurs at the 4Јa-position and OH group additions at the 5Ј-and 6Ј-positions. Therefore, the main ring of metabolite II is structurally identical to that of metabolite I.
With respect to the parent SVA, the distinct chemical shifts of protons 4 and 6 in the di-hydroxy heptanoic side chain are absent in the 1 H spectrum of metabolite II. Instead, the following shorter connectivity is seen in the TOCSY spectrum: Ϫ2.20 Ϫ ϳ1.61 Ϫ ϳ1.11, 1.18 Ϫ ϳ1.47, 1.56 Ϫ 2.26 ppm corresponding to 5-6-7-8-1Ј connectivity. The 1 H and its 13 C-correlated peaks at 2.20 and 36.5 ppm, respectively, are consistent with a ϪCH 2 COOH moiety, and they are assigned to the methylene labeled 5. The MS and NMR spectra together indicate that metabolite II is a pentanoic acid derivative of 5Ј␤,6Ј␤-dihydroxy-4Јa␣-glutathione SVA adduct (Fig. 1) Table  1 . NMR peaks corresponding to protons 4 and 6 in the heptanoic acid side chain had ␦ of 4.25 and 4.62 ppm, respectively. Hence, metabolite III was in its lactone form in the NMR sample. Again, as seen with metabolite I, the lactonization occurred during metabolite purification carried out under acidic conditions. There seem to be practically no changes in either the chemical shifts or connectivities (in the TOCSY spectrum) of protons in the heptanoic lactone and the dimethyl butoxy side chain, indicating that no oxidation has occurred on either of these moieties.
The 6ЈMe peak at 1.08 ppm (doublet) in SVA has shifted downfield to 1.23 ppm and appears as a singlet, indicating hydroxylation at the 6Ј-carbon. The SVA peaks at 5.79 ppm (3ЈH) and 5.49 ppm (5ЈH) have disappeared. Instead, new peaks are seen at 3.86 ppm (multiplet) and 3.79 ppm (singlet), indicative of two CHOH groups. The TOCSY spectrum of metabolite III shows the following connectivity: 5.85 Ϫ 3.86 Ϫ 1.94, 0.85 Ϫ 1.72 Ϫ 2.40 Ϫ 5.30 Ϫ 1.77, 2.17 ppm corresponding to protons 4Ј-3Ј-2Ј, 2ЈMe-1Ј-8Јa-8Ј-7Ј in the decalin ring. The 2Ј has moved up-field by 0.5 ppm in the metabolite spectrum, a change that can be accounted for by the loss of the ⌬ 3Ј,4Ј double bond and hydroxylation at the 3Ј-position. The remaining CHOH singlet at 3.79 ppm is assigned to the 5ЈH. A difference NOE spectrum obtained by irradiating the 6ЈMe singlet at 1.23 ppm shows a positive NOE peak at 3.79 ppm (5ЈH), thereby confirming the above assignment and also that the 5Ј-OH is in the ␤-configuration. The 3Ј-and 5Ј-methine chemical shifts are consistent with the previously identified 3Ј,5Ј-dihydrodiol-SV (Prueksaritanont et al., 1997) . Therefore, metabolite III has been identified as 3Ј,5Ј␤,6Ј␤-dihydrotriol-SVA, as shown in Fig. 1 .
Excretion of Metabolites I, II, and III in Bile. For a 5 mg/kg i.v. dose in rats, 87% (in male; n ϭ 4) and 83% (in female; n ϭ 2) of the total radioactivity is recovered in bile collected over 0 to 8 h. Metabolite I accounts for 16% (male) and 11% (female) and metabolite II for 9% (male) and 5% (female) of the total dose (Table 2) . Metabolite III was a minor metabolite, accounting for 2% (male) and 4% (female) of the total radioactivity. The two previously identified metabolites (Vickers et al., 1990a,b) were also seen, namely, 6Ј-OH-SVA at 11 and 4% and 3Ј-OH-SVA at 20 and 12% of the total radioactivity in male and female rats, respectively. For a 0.2 mg/kg i.v. dose in male dogs (n ϭ 3), glutathione adducts (metabolites I and II) were not seen. Of the 45% total radioactivity recovered during the 24-h collection period, metabolite III accounts for 4% of the total dose. Other significant oxidative metabolites found in rat and dog bile are listed in Table 2 .
Discussion
Hydrolysis of SV to SVA in rodent plasma is rapid (Vickers et al., 1990a) . Hence, metabolism of SVA is expected to give a similar metabolite profile as seen for SV in rats. In this article, structural characterizations of three new metabolites of SVA that constitute a
FIG. 4. TOCSY (80-ms mixing time) (A) and transverse ROESY (300-ms mixing time) spectra (B) of metabolite I.
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Recovery of SVA metabolites (% of total dose) in bile
Values are from pooled samples: male rats (n ϭ 4), female rats (n ϭ 2), and male dogs (n ϭ 3). dmd.aspetjournals.org significant percent (29% male and 19% female) of the total dose in rats are described. Analogous to metabolite I, the 5Ј␤,6Ј␤-dihydroxy-4Јa␣-glutathione adduct of pravastatin sodium (sodium salt of pravastatin hydroxy acid) has been previously reported to be formed both in vitro and in vivo in rats (Nakamura et al., 1991; Komai et al., 1992) . Metabolite I could be formed by two possible mechanisms. The first possibility is an initial oxidation of SVA to 6ЈOH-SVA, followed by formation of a 4Јa␤,5Ј␤-epoxide and nucleophilic attack of glutathione at the 4Јa-carbon from the sterically less hindered ␣-side. Alternatively, the epoxide may be formed first followed by oxidation at the 6Ј-position. The former possibility seems to be more likely since 6ЈOH-SVA is a significant in vivo metabolite and also no 5Ј-OH,4Јa-glutathione adduct of SV or SVA is observed.
SVA
Metabolite II is possibly a product of the ␤-oxidation pathway starting with metabolite I. Alternatively, metabolite II can also be formed by initial ␤-oxidation of the dihydroxy heptanoic acid side chain of SVA to pentanoic acid, followed by events paralleling the formation of metabolite I. Neither mechanism can be ruled out since both the pentanoic acid derivative of SVA (Prueksaritanont et al., 2001 ) and metabolite I are observed. An analog of metabolite II has not been reported previously in any of the structurally similar statins (pravastatin, lovastatin, or SV/SVA). However, ␤-oxidation pathways yielding the pentanoic acid analog are a common feature in pravastatin and other statins (Arai et al., 1988; Vickers et al., 1990b; Vyas et al., 1990; Everett at al., 1991; Komai et al., 1992; Halpin et al., 1993; Le Couteur et al., 1996; Black et al., 1999; Prueksaritanont et al., 2001) . Therefore, although not reported, it is possible that the pentanoic acid derivative similar to metabolite II is also formed from pravastatin.
Metabolite III, the 3Ј,5Ј␤,6Ј␤-dihydrotriol derivative of SVA has not been previously reported from either SV/SVA or lovastatin. It has been shown to form in vivo from the pravastatin hydroxy acid in humans and in rats (Everett et al., 1991; Komai et al., 1992) . As mentioned above, the initial site of oxidation could be the 6Ј site, followed by formation of 4Јa␤,5Ј␤-epoxide and hydrolysis, as proposed by Nakamura et al. (1991) , leading to the dihydrotriol-SVA. Based on the NOE experiment, the 6ЈMe and 5ЈH are syn to each other (in the 6Ј␤-OH, 5Ј␤-OH configuration) but the configuration at the 3Ј-position could not be conclusively determined. In the case of pravastatin, its dihydrodiol was shown to be in the 3Ј␣-OH, 5Ј␤-OH, 6Ј␤-OH configuration by comparison with a synthetic standard (Nakamura et al., 1991) .
Qualitatively, all significant bile metabolites of SV that were found in male rats were also seen in the females. However, quantitatively, they were formed in greater amounts in males versus females. Metabolites I and II together account for 25 and 16% of total i.v. dose, whereas the 3Ј-OH metabolite accounted for 20 and 12% of the i.v. dose in male and female rats, respectively. These gender differences in the metabolism of SV are consistent with previously published in vitro data (Ohtawa and Uchiyama, 1992) , which showed a higher rate of metabolism in males than in female rats. In vivo, a similar trend was observed, and the gender differences have been attributed to the different P450 isozymes responsible (CYP3A in female and CYP2C11 in male rats) for the metabolism of SV (Ishigami et al., 2001 ).
Neither of the glutathione adducts (metabolites I and II) were observed in dogs dosed with SV or SVA. It is noteworthy that the glutathione conjugates of SVA have not been observed in humans following SV or SVA administration (unpublished data on file, Merck Research Laboratories). Also, glutathione adducts analogous to metabolites I and II have not been previously reported in dogs for lovastatin and pravastatin.
Metabolite III was found to be inactive in the HMG-coenzyme A reductase inhibition assay. Metabolites I is expected to be inactive based on previous studies of the 3Ј,5Ј-dihydroxy diol metabolite of SV (Prueksaritanont et al., 1997) . Metabolite II is also expected to be inactive due to the loss of the dihydroxy heptanoic acid side chain, which is necessary for HMG-coenzyme A reductase activity (Duggan and Vickers, 1990) .
